Image Place holder

Kedar Kirtane, MD


Specialty: Hematology/Oncology
Program: Head and Neck Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)

Overview

Cancer Types Treated: Head and Neck Cancer , Thyroid Cancer

Dr. Kirtane is an  Assistant Member at Moffitt Cancer Center in the Department of Head and Neck-Endocrine Oncology. Dr. Kirtane received his MD degree from The University of Florida College of Medicine. He completed an Internal Medicine Residency at Duke University Medical Center. Dr. Kirtane completed a Hematology/Oncology Fellowship at the University of Washington and a Post-Doctoral Fellowship in Oncology at Fred Hutchinson Cancer Research Center. His clinical focus is patients with head and neck-endocrine cancers. He is interested in working with the Department of Health Outcomes and Behavior and the Department of Cancer Epidemiology to help increase access to cancer care for racial/ethnic minorities with cancer. Dr. Kirtane's research interests include the development of innovative cellular therapies for HPV-related malignancies.

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • University of Washington - Hematology/Oncology
  • Fred Hutchinson Cancer Research Center - Oncology

Residency:

  • Duke University - Internal Medicine

Medical School:

  • University of Florida - MD
Participating Trials

CLINICAL TRIAL 17716
A Biomarker-related Approach to Screening for HPV-related Oropharyngeal Cancer
Condition: Head & Neck
Intervention:
Open

CLINICAL TRIAL 18503
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib
Open

CLINICAL TRIAL 18837
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Condition: Multiple
Intervention: Dexamethasone; Rovalpituzumab Tesirine
Open

CLINICAL TRIAL 19178
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Condition: Head & Neck
Intervention: BMS-936558 (Nivolumab); Cetuximab; Erbitux (Cetuximab); Nivolumab
Open

CLINICAL TRIAL 19462
An Open-Label, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors and Lymphomas
Condition: Multiple
Intervention: Bay 1895344
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Kirtane K, Downey L, Lee SJ, Curtis JR, Engelberg RA. Intensity of End-of-Life Care for Patients with Hematologic Malignancies and the Role of Race/Ethnicity. J Palliat Med. 2018 Oct;21(10):1466-1471. Pubmedid: 29975599. Pmcid: PMC6201780.
  • Kirtane K, Lee SJ. Racial and ethnic disparities in hematologic malignancies. Blood. 2017 10;130(15):1699-1705. Pubmedid: 28724539. Pmcid: PMC5639484.